Chlordiazepoxide + clidinium bromide

Should be taken on an empty stomach. Take 30 min-1 hr before meals.

Glaucoma, myasthenia gravis, obstructive gastrointestinal diseases, paralytic ileus, ulcerative colitis, benign bladder neck obstruction, prostatic hyperplasia.

Patient with a history of drug abuse or acute alcoholism, depression, CV disease (e.g. CHF, coronary heart disease), respiratory disease. Patient subjected to heat exposure, strenuous exercise and dehydration, or receiving anticholinergic drugs. Elderly and debilitated patients. Renal and hepatic impairment. Avoid abrupt withdrawal (prolonged therapy). Patient Counselling This drug may impair physical or mental abilities, if affected, do not drive or operate machinery. Monitoring Parameters Monitor mental status, anticholinergic effects (e.g. CNS, bowel and bladder function); CBC, liver and renal function (as needed); respiratory and CV status (including orthostasis). Evaluate for history of addiction. Assess for signs and symptoms of CNS depression and paradoxical reactions (e.g. excitement, stimulation, acute rage).

Significant: Paradoxical reactions (e.g. hyperactive or aggressive behaviour), impaired core body temperature regulation, sleep-related activities (e.g. sleep-driving, cooking, and eating; making phone calls while asleep), falls, withdrawal symptoms, anticholinergic effects (e.g. xerostomia, blurred vision, urinary retention); drug tolerance or psychological and physical dependence. Blood and lymphatic system disorders: Blood dyscrasias (e.g. agranulocytosis, leucopenia). Gastrointestinal disorders: Nausea, constipation. Hepatobiliary disorders: Hepatic dysfunction, jaundice. Investigations: Changes in EEG. Metabolism and nutrition disorders: Oedema. Nervous system disorders: Ataxia, confusion, drowsiness, extrapyramidal reaction, anterograde amnesia. Reproductive system and breast disorders: Menstrual irregularities, increased and decreased libido. Skin and subcutaneous tissue disorders: Skin eruption. Vascular disorders: Syncope.

Chlordiazepoxide may increase risk of CNS effect with other CNS depressants.

Antispasmodics

N05BA02 - chlordiazepoxide ; Belongs to the class of benzodiazepine derivatives anxiolytics. Used in the management of anxiety, agitation or tension.